GSK Ponied Up $2.4B In Legal Charges In 2nd Quarter

Law360, New York (July 15, 2010, 1:25 PM EDT) -- GlaxoSmithKline PLC has disclosed a whopping £1.57 billion ($2.36 billion) legal charge tied to product liability and antitrust settlements over its troubled drugs Paxil and Avandia, revealing for the first time a £500 million settlement over allegations that the company had produced defective Paxil in a now-closed Puerto Rico factory.

The British drugmaker disclosed the second-quarter charge — more than double its total legal charges for all of 2009 — in a filing with the U.S. Securities and Exchange Commission on Thursday.

"The charge we have...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.